D. Western Therapeutics Institute, Inc. (4576.T)
Tokyo · JPY · Healthcare · Biotechnology
¥62 (-1.59%) as of
Key statistics
- Market cap
- 3.57B
- EPS (TTM)
- -11.91
- Dividend yield
- 0.00%
- 52-week range
- 60.00 – 111.00
- Beta
- 0.04
- Revenue (TTM)
- 247M
- Profit margin
- -258.70%
- Volume
- 191.70k
About D. Western Therapeutics Institute, Inc.
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; and DWR-2206, a regenerative medicine cell-product for bullous keratopathy. D. Western Therapeutics Institute, Inc. was founded in 1999 and is headquartered in Nagoya, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Nagoya, Japan
- Employees
- 19
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.